Audit: QRS - Microdosing GLP-1 for Health & Longevity
Audit conducted on 22/09/2026 18:17 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 82 |
| Failed | 0 |
| N/A | 12 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells trace to ER 431/433/435; time-to-effect to ER 490; benefits/risks to the ER tier headings; monitoring rows to the ER biomarker table (ER 522-537); gates to ER 365-403; at-a-glance to the ER Conclusion (ER 571-575). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER’s “⚠️ Conflicted” markers are carried as “, conflicted” on dementia (line 551) and on the four conflicted risks (lines 649-651). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications stay absolute; “No trial data exist below 0.25 mg” (line 457) matches ER 431; “No study has followed low-dose use beyond a few years” (line 438) matches ER 573. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from Key Interactions & Contraindications; risks only from Potential Risks & Side Effects; no Benefit- or Risk-Modifying Factor and no Risk Mitigation Strategy has leaked into another card. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, no trial names, no NCT identifiers, no expert names and no brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The lede reuses the ER Conclusion’s own register (“amount”, “blood sugar”, “unwanted effects”, ER 571-573). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Actionable dose ranges, target biomarker values and qualitative checkpoints are presented without hedging or alarm. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Items state conditions and thresholds; none issues an instruction to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Contraindications and interactions are stated as facts about populations and substances, not as directives. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should”, “advised” anywhere in the sheet’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms that remain (e.g. “gastroparesis”, “Child-Pugh Class C”, line 584) are the ER’s own precise labels that 4.3 forbids paraphrasing; the lede uses plain-language substitutes throughout. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit and risk item is reduced to the key fact; no mechanistic or magnitude text survives. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed across all cards and the footer. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal-functional-range targets (lines 676-786) and a 16-marker panel address an audience that self-monitors. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The oral-route fasting requirement (line 485) and the 6-month body-composition and grip-strength cadence (line 793) assume that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification toward a general-population reader; the sheet assumes access to laboratory panels and body-composition scanning. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The sheet foregrounds the microdose window, lean-mass preservation and inflammation markers rather than weight reduction — the longevity-audience framing of the ER. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the page title carries “Health & Longevity” (line 22). |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. | 🟢 | Route of administration is stated formally: “Subcutaneous” (lines 457, 471), “Oral semaglutide alternative” / “3 mg tablet” (lines 478-485). The lede’s “prescription medications” is the formal register. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fifteen strings match the template byte-for-byte (lines 446, 492, 534, 565, 591, 633, 665, 669-671, 801 and the four tier labels in each of Benefits and Risks). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | A name-by-name diff against the template returns every template variable; the repeatable marker_#_* and qualitative_item_# anchors are expanded to 16 and 5 instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | website="evidence_review", website="audit" and website="full_review" are untouched (lines 423, 426, 440); a full diff against the template shows no change outside the metadata block and the variable spans. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Semaglutide microdose range”, “Tirzepatide microdose range”, “Oral semaglutide alternative” are the ER’s bold labels verbatim (ER 431-435); interaction labels are the ER’s bold labels with only the explanatory gloss trimmed per 9.5. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels track the ER’s own terms at ER 490; benefit and risk items reuse the ER’s #### headings; monitoring row names are the ER table’s biomarker names verbatim. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | A scan for 🟩 / 🟥 / 🟨 / ⚠ returns nothing; tiering is carried by the <strong> labels and the card palettes. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to key facts — glosses, magnitudes, confidence intervals, mechanisms and attributions are all stripped — so the per-section condensation required here has been applied; the remaining length is driven by the completeness that 8.2, 9.2, 12.1, 13.1 and 14.2 mandate. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The comment opens on line 2, immediately after <!doctype html> on line 1, and closes on line 14 before any other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It sits inside an HTML comment and no metadata value is repeated in the head or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, and it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: microdosing_glp_1_2026-0918-0931_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.22, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0922-1807. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s own name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Microdosing GLP-1 for Health & Longevity - Quick Reference Sheet. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Microdosing GLP-1 for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/22/2026, matching qrs_creation_date: 2026-0922-1807. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415-428) is structurally identical to the template; the ER’s long “Also known as” list was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | The opening clause (line 434) names the kind (“the prescription medications”) and the use (“for diabetes and weight reduction”) before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences compress the ER Conclusion’s definition, benefit set, dose-scaling of adverse effects and duration gap (ER 571-573). |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 64 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Definition → ER 571; glycaemic/blood-pressure/inflammation improvement and partial fat loss → ER 571; dose-scaling of unwanted effects → ER 573; absence of long-term follow-up → ER 573. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “the main blood marker of low-grade inflammation” replaces CRP; “blood sugar” replaces HbA1c/glycaemic control. The only acronym is the intervention’s own name, which the sentence immediately glosses. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect size, hazard ratio or confidence interval appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map to the ER’s “Populations who should avoid Microdosing GLP-1” list (ER 389-403). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Eight ER bullets, eight QRS items, none added or dropped. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 568-587: eight discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | “— absolute contraindication” (ER 389, 391) and the ketoacidosis rationale (ER 403) are stripped; the MEN2 and Child-Pugh glosses are removed while the classes themselves remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “within 2 months” (line 574), “HbA1c above 9%” and “until ophthalmological review” (lines 576-577), “below 18.5 kg/m²” (line 580), “(Child-Pugh Class C)” and “eGFR below 15 mL/min/1.73 m²” (line 584) all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets contain no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is populated. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items map to the ER’s interaction bullets (ER 365-385). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eleven ER interaction bullets, eleven QRS items; no overlap with the eight contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 594-623: eleven discrete <li> elements. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “Caution —” / “Monitor —” clauses and every mitigation sentence are stripped; each item is the bold label plus its drug list. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every named-drug list survives (lines 594-622); only the ER’s explanatory glosses (e.g. “drugs that make the pancreas release insulin”, “appetite suppressants”) are trimmed. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets contain no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is populated. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | The three cells map to the first three bullets of the ER Therapeutic Protocol section (ER 431-435). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The two injectable dose ranges and the oral alternative are the only bullets that state a usable dose; the remaining bullets cover rationale, timing and modifiers. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects exist and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-derived content (lines 450-487); none is a placeholder. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Glycaemic markers, C-reactive protein and body composition — the three intervals in ER 490 that correspond to graded benefits. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | All three map to High-tier benefits and follow the ER’s own High-tier order: glycaemic control, inflammation, fat-mass reduction (ER 149-165). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three time-to-effect intervals; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine variables carry ER-derived content (lines 498-526). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (ER 490). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fifteen items are the ER’s benefit headings across the four tiers (ER 147-241). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 536-558). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details. No mechanistic explanations, etc. Just the key fact. | 🟢 | Every ER Magnitude: paragraph is dropped; items are bare headings. The retained “, conflicted” reproduces the ER’s own ⚠️ marker, which 1.2 requires. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain anywhere in the Benefits card. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All thirteen items are the ER’s risk headings across the four tiers (ER 265-345). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 635-659). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details. No mechanistic explanations, etc. Just the key fact. | 🟢 | Every ER Magnitude: paragraph and mechanism sentence is dropped; the retained “, conflicted” reproduces the ER’s own ⚠️ marker per 1.2. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain anywhere in the Risks card. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence trace to the ER Monitoring Protocol & Defining Success section (ER 516-537). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All sixteen rows of the ER biomarker table appear, with names, optimal ranges and “Why Measure It?” text carried verbatim (lines 676-786). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 791-795 reproduce the ER’s cadence paragraph (ER 518): 4-week symptom check, 12-week panel, 6-monthly thereafter, body composition and grip strength every 6 months, lipid and inflammation panel annually. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The five items map to the ER’s qualitative-marker bullets (ER 541-549). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Five ER bullets, five QRS items (lines 803-830); only the ER’s parenthetical asides are trimmed. |
Issues 22/09/2026 18:17
Pass rate 100.00%. No issues found.
Issues 22/09/2026 18:11
- 1.1 — Lede narrows class to injections: [at_a_glance] (line 434) describes the intervention as “the injected prescription medications”, which the ER does not support and which contradicts the QRS’s own [action_3] “Oral semaglutide alternative — 3 mg daily” (lines 478-488).
Fixes 22/09/2026 18:11
- 1.1 — Lede narrows class to injections: Removed “injected” from [at_a_glance], so the lede now reads “the prescription medications for diabetes and weight reduction”, consistent with the ER and with the sheet’s own oral semaglutide cell.